Latest News

FDA Approves Johnson & Johnson’s Tremfya for Crohn Disease
FDA Approves Johnson & Johnson’s Tremfya for Crohn Disease

March 21st 2025

Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.

Johnson & Johnson to Invest Over $55 Billion in US Manufacturing Facilities
Johnson & Johnson to Invest Over $55 Billion in US Manufacturing Facilities

March 21st 2025

Phase III Trial Shows Novartis’ Gene Therapy Significantly Improves Spinal Muscular Atrophy Outcomes
Phase III Trial Shows Novartis’ Gene Therapy Significantly Improves Spinal Muscular Atrophy Outcomes

March 21st 2025

Stock.adobe.com
ABPI Restores Novo Nordisk’s Membership

March 21st 2025

Kimberley Chiang, CoverMyMeds
Strategies to Address Rising Medication Costs & Improve Patient Access

March 21st 2025

Emerging Biopharma Launches: Strategizing in Today’s Global Market

A look at the current landscape and how young companies can set the stage for product launch.

 A look at the current landscape and how young companies can set the stage for product launch.

Conference Coverage

View All
JPM25: Oncology Outlook for 2025
JPM25: Oncology Outlook for 2025

January 20th 2025

Stock.adobe.com
NVIDIA Announces Pharma Partnerships to Expand AI

January 15th 2025

Stock.adobe.com
Moderna Details Product Pipeline and Finances Ahead of JP Morgan Presentation

January 14th 2025

Stock.adobe.com
Biohaven Details Pipeline Update At JP Morgan Conference

January 14th 2025

Latest Videos
Podcasts
Jennifer Butler

All News